NEW YORK (GenomeWeb) – Catalyst Pharmaceuticals has signed an agreement to use Biocept's Target Selector liquid biopsy platform to screen for cancer in patients enrolled in a clinical trial of its rare disease drug Firdapse (amifampridine phosphate).

Firdapse is currently approved in the EU to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease often associated with malignancies such as small cell lung cancer. Catalyst holds the drug's North American rights.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.